The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age
Identifieur interne : 001C06 ( Main/Exploration ); précédent : 001C05; suivant : 001C07The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age
Auteurs : Yoshio Hirota [Japon] ; Masaro Kaji [Japon] ; Saburo Ide [Japon] ; Shuro Goto [Japon] ; Tetsuya Oka [Japon]Source :
- Vaccine [ 0264-410X ] ; 1996.
English descriptors
- Teeft :
- Achievement rate, Achievement rates, Antibody, Antibody induction, Antibody response, Antibody responses, Attack rate ratio, Attack survey, Attenuated influenza, Confidence interval, Difference method, Elderly persons, Entire sample, Epidemic peak, Greater rise, Greater titer, Greater titer rise, Healthy adults, Hirota, Hlnl, Independent effect, Independent effects, Influenza, Influenza vaccine, Influenza vaccines, Interaction term, Japanese scale, Multivac, Multivac group, Multivac groups, National institute, Other hand, Poor antibody response, Poor response, Postvaccination, Postvaccination sera, Postvaccination titer, Potential predictors, Preexisting antibody, Present study, Prevac titerxage, Prevaccination, Prevaccination antibody, Prevaccination table, Prevaccination titer, Prevaccination titer levels, Prevaccination titers, Previous studies, Previous vaccinations, Protective level, Rank test, Response rate, Response rates, Serum antibody, Significant effect, Study subjects, Titer, Titer rise, Trend test, Unbalanced data, Vaccination, Vaccination history, Vaccine, Vaccine antigens, Vaccine efficacy, Vaccine strain, Variance, Virus vaccines, Wilcoxon rank, Wilcoxon test.
Abstract
Abstract: The immunogenicity of the trivalent split-virus influenza vaccine was investigated among 70 healthy adults (mean age: 48.5, range: 36–68). The vaccine antigens were: A/Yamagata/32/89 (H1N1); A/Beijing/352/89 (H3N2); and B/Bangkok/163/90. Regarding the entire sample, the vaccine induced a tenfold or more rise on the average in the hemagglutination inhibition (HAI) antibody to each antigen. The response rates (greater than or equal to a fourfold rise) were about 90% or more among those with a prevaccination titer ≤1:64 (equivalent to ≤1:16 on the Western scale: in Japan, the HAI titers are expressed by the final, and not the initial, dilution of the serum; from hereon our findings will be expressed using the Japanese scale), whereas they were 0–50% at ≥1:128. Thus, the prevaccination titer was negatively associated with antibody induction. The achievement rates (postvaccination titer ≥1:128) among those with a prevaccination titer <1:16 remained at 48–68%. Regarding the analysis of variance, a significant effect on antibody induction was indicated for the prevaccination titer (P≤0.002), but not for age (P≥0.425). The interaction between the prevaccination titer and age was significant for A/Yamagata (P=0.030), while it was also suggestive for A/Beijing (P=0.054): as age increased, those with no preexisting antibody (<1:16) showed greater titer rises, in contrast to the smaller rises among those with a titer ≥1:16. Based on the attack survey conducted separately, the vaccine efficacy on influenza-like illnesses with fever ≥37°C and ≥37.5°C was calculated to be 16% (95% confidence interval: −66% to 57%) and 37% (−55% to 74%), respectively.
Url:
DOI: 10.1016/S0264-410X(96)00153-3
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001321
- to stream Istex, to step Curation: 001321
- to stream Istex, to step Checkpoint: 000985
- to stream Main, to step Merge: 001C74
- to stream Main, to step Curation: 001C06
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age</title><author><name sortKey="Hirota, Yoshio" sort="Hirota, Yoshio" uniqKey="Hirota Y" first="Yoshio" last="Hirota">Yoshio Hirota</name></author><author><name sortKey="Kaji, Masaro" sort="Kaji, Masaro" uniqKey="Kaji M" first="Masaro" last="Kaji">Masaro Kaji</name></author><author><name sortKey="Ide, Saburo" sort="Ide, Saburo" uniqKey="Ide S" first="Saburo" last="Ide">Saburo Ide</name></author><author><name sortKey="Goto, Shuro" sort="Goto, Shuro" uniqKey="Goto S" first="Shuro" last="Goto">Shuro Goto</name></author><author><name sortKey="Oka, Tetsuya" sort="Oka, Tetsuya" uniqKey="Oka T" first="Tetsuya" last="Oka">Tetsuya Oka</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:54CB1E6B488CBF8626F2DF25D03ACD77B6AA34A7</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1016/S0264-410X(96)00153-3</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-VSM1PWWF-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001321</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001321</idno><idno type="wicri:Area/Istex/Curation">001321</idno><idno type="wicri:Area/Istex/Checkpoint">000985</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000985</idno><idno type="wicri:doubleKey">0264-410X:1996:Hirota Y:the:hemagglutination:inhibition</idno><idno type="wicri:Area/Main/Merge">001C74</idno><idno type="wicri:Area/Main/Curation">001C06</idno><idno type="wicri:Area/Main/Exploration">001C06</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age</title><author><name sortKey="Hirota, Yoshio" sort="Hirota, Yoshio" uniqKey="Hirota Y" first="Yoshio" last="Hirota">Yoshio Hirota</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka</wicri:regionArea><orgName type="university">Université de Kyūshū</orgName><placeName><settlement type="city">Fukuoka</settlement><region type="province">Kyūshū</region><region type="prefecture">Préfecture de Fukuoka</region></placeName></affiliation></author><author><name sortKey="Kaji, Masaro" sort="Kaji, Masaro" uniqKey="Kaji M" first="Masaro" last="Kaji">Masaro Kaji</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Kurume University, Asahi-machi, Kurume-shi</wicri:regionArea><wicri:noRegion>Kurume-shi</wicri:noRegion></affiliation></author><author><name sortKey="Ide, Saburo" sort="Ide, Saburo" uniqKey="Ide S" first="Saburo" last="Ide">Saburo Ide</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Public Health, Faculty of Medicine 60, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka</wicri:regionArea><orgName type="university">Université de Kyūshū</orgName><placeName><settlement type="city">Fukuoka</settlement><region type="province">Kyūshū</region><region type="prefecture">Préfecture de Fukuoka</region></placeName></affiliation></author><author><name sortKey="Goto, Shuro" sort="Goto, Shuro" uniqKey="Goto S" first="Shuro" last="Goto">Shuro Goto</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto</wicri:regionArea><wicri:noRegion>Kurnamoto</wicri:noRegion></affiliation></author><author><name sortKey="Oka, Tetsuya" sort="Oka, Tetsuya" uniqKey="Oka T" first="Tetsuya" last="Oka">Tetsuya Oka</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>The Chemo-Sero-Therapeutic Research Institute, Okubo 1-6-1, Kurnamoto</wicri:regionArea><wicri:noRegion>Kurnamoto</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996">1996</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">17–18</biblScope><biblScope unit="page" from="1597">1597</biblScope><biblScope unit="page" to="1602">1602</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Achievement rate</term><term>Achievement rates</term><term>Antibody</term><term>Antibody induction</term><term>Antibody response</term><term>Antibody responses</term><term>Attack rate ratio</term><term>Attack survey</term><term>Attenuated influenza</term><term>Confidence interval</term><term>Difference method</term><term>Elderly persons</term><term>Entire sample</term><term>Epidemic peak</term><term>Greater rise</term><term>Greater titer</term><term>Greater titer rise</term><term>Healthy adults</term><term>Hirota</term><term>Hlnl</term><term>Independent effect</term><term>Independent effects</term><term>Influenza</term><term>Influenza vaccine</term><term>Influenza vaccines</term><term>Interaction term</term><term>Japanese scale</term><term>Multivac</term><term>Multivac group</term><term>Multivac groups</term><term>National institute</term><term>Other hand</term><term>Poor antibody response</term><term>Poor response</term><term>Postvaccination</term><term>Postvaccination sera</term><term>Postvaccination titer</term><term>Potential predictors</term><term>Preexisting antibody</term><term>Present study</term><term>Prevac titerxage</term><term>Prevaccination</term><term>Prevaccination antibody</term><term>Prevaccination table</term><term>Prevaccination titer</term><term>Prevaccination titer levels</term><term>Prevaccination titers</term><term>Previous studies</term><term>Previous vaccinations</term><term>Protective level</term><term>Rank test</term><term>Response rate</term><term>Response rates</term><term>Serum antibody</term><term>Significant effect</term><term>Study subjects</term><term>Titer</term><term>Titer rise</term><term>Trend test</term><term>Unbalanced data</term><term>Vaccination</term><term>Vaccination history</term><term>Vaccine</term><term>Vaccine antigens</term><term>Vaccine efficacy</term><term>Vaccine strain</term><term>Variance</term><term>Virus vaccines</term><term>Wilcoxon rank</term><term>Wilcoxon test</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The immunogenicity of the trivalent split-virus influenza vaccine was investigated among 70 healthy adults (mean age: 48.5, range: 36–68). The vaccine antigens were: A/Yamagata/32/89 (H1N1); A/Beijing/352/89 (H3N2); and B/Bangkok/163/90. Regarding the entire sample, the vaccine induced a tenfold or more rise on the average in the hemagglutination inhibition (HAI) antibody to each antigen. The response rates (greater than or equal to a fourfold rise) were about 90% or more among those with a prevaccination titer ≤1:64 (equivalent to ≤1:16 on the Western scale: in Japan, the HAI titers are expressed by the final, and not the initial, dilution of the serum; from hereon our findings will be expressed using the Japanese scale), whereas they were 0–50% at ≥1:128. Thus, the prevaccination titer was negatively associated with antibody induction. The achievement rates (postvaccination titer ≥1:128) among those with a prevaccination titer <1:16 remained at 48–68%. Regarding the analysis of variance, a significant effect on antibody induction was indicated for the prevaccination titer (P≤0.002), but not for age (P≥0.425). The interaction between the prevaccination titer and age was significant for A/Yamagata (P=0.030), while it was also suggestive for A/Beijing (P=0.054): as age increased, those with no preexisting antibody (<1:16) showed greater titer rises, in contrast to the smaller rises among those with a titer ≥1:16. Based on the attack survey conducted separately, the vaccine efficacy on influenza-like illnesses with fever ≥37°C and ≥37.5°C was calculated to be 16% (95% confidence interval: −66% to 57%) and 37% (−55% to 74%), respectively.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Kyūshū</li><li>Préfecture de Fukuoka</li></region><settlement><li>Fukuoka</li></settlement><orgName><li>Université de Kyūshū</li></orgName></list><tree><country name="Japon"><region name="Kyūshū"><name sortKey="Hirota, Yoshio" sort="Hirota, Yoshio" uniqKey="Hirota Y" first="Yoshio" last="Hirota">Yoshio Hirota</name></region><name sortKey="Goto, Shuro" sort="Goto, Shuro" uniqKey="Goto S" first="Shuro" last="Goto">Shuro Goto</name><name sortKey="Ide, Saburo" sort="Ide, Saburo" uniqKey="Ide S" first="Saburo" last="Ide">Saburo Ide</name><name sortKey="Kaji, Masaro" sort="Kaji, Masaro" uniqKey="Kaji M" first="Masaro" last="Kaji">Masaro Kaji</name><name sortKey="Oka, Tetsuya" sort="Oka, Tetsuya" uniqKey="Oka T" first="Tetsuya" last="Oka">Tetsuya Oka</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C06 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C06 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:54CB1E6B488CBF8626F2DF25D03ACD77B6AA34A7
|texte= The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age
}}
| This area was generated with Dilib version V0.6.33. |  |